#626 The use of plasmajet® in the treatment of vulvar intraepithelial neoplasia: results from 48 patients in a UK gynaecological cancer centre

• DOI: 10.1136/ijgc-2023-esgo.827
• Publication Date: 2023-09-28T10:43:21Z
• Authors: Natasha Rinne; Shriya Varghese; Stacey Bryan; Benjamin Jones; Sadaf Ghaem-Maghami; Srdjan Saso; James Richard Smith
• Keywords: Vulvar intraepithelial neoplasia

<h3>Introduction/Background</h3> Incidence rates of vulval cancer have risen by over 17% since the 1990s. Development is secondary to cellular changes resulting in vulvar intraepithelial neoplasia (VIN), with VIN II and III carrying an increased risk developing malignancy. Wide local excision considered gold standard treatment. Plasmajet®, a relatively new device designed produce jet natural argon plasma used vaporise tissues, being laparoscopic/open treatment number malignancies as alternative tumour excision. To date, long-term data on safety outcome use Plasmajet® vulva lacking. Here we describe largest UK series gynaecological surgery. <h3>Methodology</h3> Women I-III confirmed biopsy were consented prior surgery for Plasmajet®. All procedures performed under general anaesthetic by/under supervision lead consultant. Power settings per manufacturer's instructions. Patients seen two weeks post-operatively then every 3–6 months. A retrospective audit was undertaken between September 2014 to/including 2022 tertiary oncology centre. histological diagnosis included collected on; demographics, BMI, comorbidities, regular medications, smoking, HPV status, smear results, duration, outcome. <h3>Results</h3> lost follow-up, who transferred care, or died from unrelated causes, excluded. 48 women received total 131 treatments (1–7), complication rate 6.87% (Grade I-III). Median duration first disease progression 18 months (10–64), 16.67% (mortality 2.08%) patients II-III. 10.42% discharged 12.48% active follow-up. <h3>Conclusion</h3> The results this study show be effective minimising II-III progression, low complication. <h3>Disclosures</h3> Nil